Dare Bioscience receives NIH funding extension for preterm birth treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Wall St set to open higher after June jobs report eases rate hike bets
- Oil falls for a third straight day after US, Iran conclude talks in Doha
- Dollar eases as yen gains ahead of US payrolls, chipmaker stocks struggle
- Meta Platforms stock surges 8% on cloud business plans
- Humanoid robot component stocks surge on supply-chain optimism
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth
March 16, 2026 8:01 AM EDT Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through November 2026
DARE-PTB1 targets preterm birth, for which there are no FDA-approved treatment options
Award reflects Daré's strategy of leveraging non-dilutive grant funding to advance a deep, differentiated pipeline addressing the most persistent unmet needs in women's health
SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in womens health between promising science and real-world solutions, today announced... More
